Human immunodeficiency virus and hepatitis C virus co-infection: Epidemiology, natural history and the situation in China

Chinese Medical Journal

Volumn 122, Issue 1, 2009, Pages 93-97

  Lu, Ying ^a   Robinson, Matthew ^b   Zhang, Fu Jie ^c  

^a LANZHOU UNIVERSITY   (China)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

Author keywords

Co infection; Hepatitis C virus; Human immunodeficiency virus

Indexed keywords

ANTIRETROVIRUS AGENT; ATAZANAVIR; DIDANOSINE; INDINAVIR; NEVIRAPINE; PEGINTERFERON; RIBAVIRIN; RITONAVIR; STAVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANEMIA; ARTICLE; BILIRUBIN BLOOD LEVEL; BLOOD TRANSFUSION; CHINA; COMORBIDITY; DEPRESSION; DISEASE COURSE; DISORDERS OF MITOCHONDRIAL FUNCTIONS; ENZYME LINKED IMMUNOSORBENT ASSAY; EPIDEMIOLOGICAL DATA; FATTY LIVER; FLU LIKE SYNDROME; HEMATOLOGIC DISEASE; HEPATITIS C; HEPATITIS C VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERSENSITIVITY REACTION; INCIDENCE; LIVER CELL CARCINOMA; LIVER DISEASE; LIVER INJURY; MEDICAL DECISION MAKING; PATIENT COMPLIANCE; PREVALENCE; PROGNOSIS; SEXUAL TRANSMISSION; SIDE EFFECT; VERTICAL TRANSMISSION; VIRUS TRANSMISSION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANTIVIRAL AGENTS; CHINA; HEPACIVIRUS; HEPATITIS C; HIV; HIV INFECTIONS; HUMANS; INTERFERON ALFA-2A; POLYETHYLENE GLYCOLS; RIBAVIRIN;

EID: 60649097790     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2009.01.017     Document Type: Article

References (44)

1. Rockstroh JK, Spengler U. HIV and hepatitis C virus co-infection. Lancet Infect Dis 2004; 4: 437-444.
2. Soriano V, Garcia-Samaniego J, Rodriguez-Rosado R, Gonzalez J, Pedreira J. Hepatitis C and HIV infection: biological, clinical, and therapeutic implications. J Hepatol 1999; 31 Suppl 1: s119-s123.
3. Valle Tovo C, Alves de Mattos A, Ribeiro de Souza A, Ferrari de Oliveira Rigo J, Lerias de Almeida PR, Galperim B, et al. Impact of human immunodeficiency virus infection in patients infected with the hepatitis C virus. Liver Int 2007; 27: 40-46.
4. Verucchi G, Calza L, Manfredi R, Chiodo F. Human immunodeficiency virus and hepatitis C virus coinfection: epidemiology, natural history, therapeutic options and clinical management. Infection 2004; 32: 33-46.
5. Thomas DL, Villano SA, Riester KA, Hershow R, Mofenson LM, Landesman SH, et al. Perinatal transmission of hepatitis C virus from human immunodeficiency virus type 1-infected mothers. Women and Infants Transmission Study. J Infect Dis 1998; 177: 1480-1488.
6. Browne R, Asboe D, Gilleece Y, Atkins M, Mandalia S, Gazzard B, et al. Increased numbers of acute hepatitis C infections in HIV positive homosexual men; is sexual transmission feeding the increase? Sex Transm Infect 2004; 80: 326-327.
7. Denis F, Adjide CC, Rogez S, Delpeyroux C, Rogez JP, Weinbreck P. Seroprevalence of HBV, HCV and HDV hepatitis markers in 500 patients infected with the human immunodeficiency virus. Pathol Biol 1997; 45: 701-708.
8. Roca B, Suarez I, Gonzalez J, Garrido M, de la Fuente B, Teira R, et al. Hepatitis C virus and human immunodeficiency virus coinfection in Spain. J Infect 2003; 47: 117-124.
9. Sherman KE, Rouster SD, Chung RT, Rajicic N. Hepatitis C virus prevalence among patients infected with human immunodeficiency virus: a cross-sectional analysis of the US adult AIDS Clinical Trials Group. Clin Infect Dis 2002; 34: 831-837.
10. Sulkowski MS, Thomas DL. Hepatitis C in the HIV-infected person. Ann Intern Med 2003; 138: 197-207.
11. Gibb DM, Goodall RL, Dunn DT, Healy M, Neave P, Cafferkey M, et al. Mother-to-child transmission of hepatitis C virus: evidence for preventable peripartum transmission. Lancet 2000; 356: 904-907.
12. Resti M, Azzari C, Galli L, Zuin G, Giacchino R, Bortolotti F, et al. Maternal drug use is a preeminent risk factor for mother-to-child hepatitis C virus transmission: results from a multicenter study of 1372 mother-infant pairs. J Infect Dis 2002; 185: 567-572.
13. Zhang WD, Xi YL, Zhang MX, Duan GC. Co-infection of HIV, HBV, and HCV in a village with high prevalence rate of blood-related AIDS. J Zhengzhou Univ (Med Sci) (Chin) 2006; 2: 254-256.
14. Dong RL, Wang N, Qiao XC, Ding GW, Jia WQ, Shi XM. Investigation on HIV-1 co-infection with HCV and HBV in commercial blood donators. Chin J Epidemiol (Chin) 2007; 12: 1420-1422.
15. Wang YC, Xu SH, Li XH, Song AJ, Jia XR, Zhang H. A study on the prevalence rates of human immunodeficiency virus, hepatitis B virus and hepatitis C virus infections in intravenous drug users. Chin J Epidemiol (Chin) 2006; 9: 777-779.
16. Li L, Bao ZY, Sui HS, Liu SY, Zhuang DM, Liu YJ. Investigation on HCV co-infection in HIV-infected people in some areas of China. Chin J AIDS & STD (Chin) 2008; 1: 9-11.
17. Jiang LJ, Yin H. The report of co-infection of anti-HIV-positive and the other positive signs. Endemic Dis Bull (Chin) 2007; 4: 115.
18. Lü SQ, Li HP, Yu WL. Investigation and analysis of different HIV infected groups people co-infected with HCV. Capital Med (Chin) 2007; 20: 28.
19. Soriano V, Sulkowski M, Bergin C, Hatzakis A, Cacoub P, Katlama C, et al. Care of patients with chronic hepatitis C and HIV co-infection: recommendations from the HIV-HCV International Panel. AIDS 2002; 16: 813-828.
20. Graham CS, Baden LR, Yu E, Mrus JM, Carnie J, Heeren T, et al. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect Dis 2001; 33: 562-569.
21. Garcia-Samaniego J, Rodriguez M, Berenguer J, Rodriguez-Rosado R, Carbo J, Asensi V, et al. Hepatocellular carcinoma in HIV-infected patients with chronic hepatitis C. Am J Gastroenterol 2001; 96: 179-183.
22. Sulkowski MS. Viral hepatitis and HIV coinfection. J Hepatol 2008; 48: 353-367.
23. Koziel MJ. Influence of HIV co-infection on hepatitis C immunopathogenesis. J Hepatol 2006; 44: 14-18.
24. Mehta SH, Cox A, Hoover DR, Wang XH, Mao Q, Ray S, et al. Protection against persistence of hepatitis C. Lancet 2002; 359: 1478-1483.
25. Di Martino V, Rufat P, Boyer N, Renard P, Degos F, Martinot-Peignoux M, et al. The influence of human immunodeficiency virus coinfection on chronic hepatitis C in injection drug users: a long-term retrospective cohort study. Hepatology 2001; 34: 1193-1199.
26. Beld M, Penning M, Lukashov V, McMorrow M, Roos M, Pakker N, et al. Evidence that both HIV and HIV-induced immunodeficiency enhance HCV replication among HCV seroconverters. Virology 1998; 244: 504-512.
27. Blackard JT, Sherman KE. HCV/HIV co-infection: time to re-evaluate the role of HIV in the liver? J Viral Hepat 2008; 15: 323-330.
28. Cooper CL, Cameron DW. Review of the effect of highly active antiretroviral therapy on hepatitis C virus (HCV) RNA levels in human immunodeficiency virus and HCV coinfection. Clin Infect Dis 2002; 35: 873-879.
29. Balasubramanian A, Groopman JE, Ganju RK. Underlying pathophysiology of HCV infection in HIV-positive drug users. J Addict Dis 2008; 27: 75-82.
30. Rockstroh JK. Influence of viral hepatitis on HIV infection. J Hepatol 2006; 44: 25-27.
31. Chung RT, Kim AY, Polsky B. HIV/Hepatitis B and C co-infection: pathogenic interactions, natural history and therapy. Antivir Chem Chemother 2001; 12 Suppl 1: s73-s91.
32. De Luca A, Bugarini R, Lepri AC, Puoti M, Girardi E, Antinori A, et al. Coinfection with hepatitis viruses and outcome of initial antiretroviral regimens in previously naive HIV-infected subjects. Arch Intern Med 2002; 162: 2125-2132.
33. Greub G, Ledergerber B, Battegay M, Grob P, Perrin L, Furrer H, et al. Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study. Lancet 2000; 356: 1800-1805.
34. Callens S, Bottieau E, Michielsen P, Colebunders R. Pegylated interferon alpha-2b plus ribavirin as therapy for chronic hepatitis C in HIV-infected patients. AIDS 2004; 18: 131.
35. Soriano V, Puoti M, Sulkowski M, Cargnel A, Benhamou Y, Peters M, et al. Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel. AIDS 2007; 21: 1073-1089.
36. Alter MJ. Epidemiology of viral hepatitis and HIV co-infection. J Hepatol 2006; 44: 6-9.
37. Sterling RK, Lissen E, Clumeck N, Sola R, Correa MC, Montaner J, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 2006; 43: 1317-1325.
38. Wilson LE, Torbenson M, Astemborski J, Faruki H, Spoler C, Rai R, et al. Progression of liver fibrosis among injection drug users with chronic hepatitis C. Hepatology 2006; 43: 788-795.
39. de Ledinghen V, Douvin C, Kettaneh A, Ziol M, Roulot D, Marcellin P, et al. Diagnosis of hepatic fibrosis and cirrhosis by transient elastography in HIV/hepatitis C virus-coinfected patients. J Acquir Immune Defic Syndr 2006; 41: 175-179.
40. Nunes D, Fleming C, Offner G, O'Brien M, Tumilty S, Fix O, et al. HIV infection does not affect the performance of noninvasive markers of fibrosis for the diagnosis of hepatitis C virus-related liver disease. J Acquir Immune Defic Syndr 2005; 40: 538-544.
41. Kelleher TB, Mehta SH, Bhaskar R, Sulkowski M, Astemborski J, Thomas DL, et al. Prediction of hepatic fibrosis in HIV/HCV co-infected patients using serum fibrosis markers: the SHASTA index. J Hepatol 2005; 43: 78-84.
42. Epidemiological Fact Sheets on HIV and AIDS. Geneva: World Health Organization, 2008. (Accessed September 2, 2008 at http://www.who.int/ hiv/pub/epidemiology/pubfacts/en/.)
43. Zhang F, Haberer JE, Wang Y, Zhao Y, Ma Y, Zhao D, et al. The Chinese free antiretroviral treatment program: challenges and responses. AIDS 2007; 21 Suppl 8: s143-s148.
44. Zhang F, Dou Z, Yu L, Xu J, Jiao JH, Wang N, et al. The effect of highly active antiretroviral therapy on mortality among HIV-infected former plasma donors in China. Clin Infect Dis 2008; 47: 825-833.